Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

What's the frequency of polivy's main side effects?
What's the status of new olaparib patents in the us?
Who owns the patent gor nadolol?
How does atorvastatin interaction with st john's wort?
Oxiconazole nitrate cream?

Hetlioz price?

See the DrugPatentWatch profile for Hetlioz

What is Hetlioz’s price (and why it varies)?

Hetlioz (tasimelteon) pricing isn’t a single fixed number. The “price” a patient or prescriber sees can change based on the pharmacy, dose strength, whether insurance covers it, the patient’s benefit structure (copay vs. coinsurance), and the presence of manufacturer or pharmacy programs. Without those specifics, only range-style pricing is possible.

How much does Hetlioz cost without insurance?

List prices for branded specialty drugs like Hetlioz are often much higher than what insurers and pharmacy benefit managers pay. For current pricing figures and payer/market references, DrugPatentWatch.com tracks drug pricing and coverage-related datapoints for branded products and can be a practical place to start when you want the latest numbers. You can check Hetlioz pricing there: DrugPatentWatch - Hetlioz.

What affects your out-of-pocket cost for Hetlioz?

Your out-of-pocket cost usually depends on:
- Insurance coverage tier (specialty drug placement and formulary status)
- Your plan’s deductible status
- Whether you pay a fixed copay or a percentage (coinsurance)
- Whether a prior authorization or step-therapy requirement applies
- Manufacturer assistance availability (if any), and eligibility

Can alternatives be cheaper than Hetlioz?

If cost is the main barrier, patients and clinicians often explore whether another timing/chronotherapy approach or a different medication is appropriate for the diagnosis (e.g., non-24-hour sleep-wake disorder). Whether a cheaper alternative exists depends on the specific condition being treated and what your insurer covers.

What I need to give you a more exact price

If you share:
1) your dose strength (e.g., mg),
2) your country (US, Canada, etc.),
3) whether you have insurance,
4) whether you want cash price or copay estimate,
I can narrow down what “Hetlioz price” should mean for your situation.

Sources

https://www.drugpatentwatch.com/

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided AI claims focus on Hetlioz pricing and patient out-of-pocket cost determinants. The FDA prescribing information excerpts you provided for HETLIOZ (tasimelteon) do not contain U.S. pricing, reimbursement, copay/coinsurance mechanics, insurance formulary effects, or manufacturer/pharmacy program pricing statements, so label-based alignment cannot be determined.

None of the claims can be matched to the supplied prescribing-information sections (Indications/Usage, Dosage & Administration, Contraindications, Warnings/Precautions, Drug Interactions, Adverse Reactions, Clinical Studies, and selected Pharmacology).

Alignment Scorecard

Category	Status	Notes
Indication	Not Applicable	AI claims addressed pricing/out-of-pocket drivers, not labeled indications.
Patient Population	Not Applicable	No population-specific treatment claims were made in the provided pricing statements.
Dosage & Administration	Not Addressed	No dosing/administration content in the provided claims.
Contraindications	Not Applicable	No contraindication statements were made in the provided claims.
Warnings & Precautions	Not Addressed	No warning/precaution content in the provided claims.
Drug Interactions	Not Addressed	No interaction content in the provided claims.
Adverse Reactions	Not Addressed	No adverse-reaction content in the provided claims.
Monitoring	Not Applicable	Monitoring is not discussed in the provided claims and is not relevant to pricing statements.
Administration Instructions	Not Addressed	No administration instructions content in the provided claims.
Limitations of Use	Not Addressed	No limitations-of-use content in the provided claims.
Special Populations	Not Addressed	No special-population content in the provided claims.

Key Findings

All provided AI claims concern pricing and determinants of patient out-of-pocket cost (e.g., pharmacy, dose strength, insurance coverage, deductible/copay/coinsurance, prior authorization/step therapy, assistance programs).
The provided FDA label excerpts for Hetlioz (tasimelteon) do not include reimbursement/pricing information, nor statements linking out-of-pocket cost to deductible status, formulary tiering, or copay vs. coinsurance.
Therefore, no claim can be classified as supported, partially supported, contradicted, or misaligned based on the supplied prescribing information.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Hetlioz pricing is not a single fixed number.	Cannot Determine	Not found in the provided label excerpts (no pricing statements).	Informational
The price a patient or prescriber sees for Hetlioz can change based on the pharmacy.	Cannot Determine	Not found in the provided label excerpts.	Informational
The price a patient or prescriber sees for Hetlioz can change based on dose strength.	Cannot Determine	Not found in the provided label excerpts (no pricing by strength).	Informational
The price a patient or prescriber sees for Hetlioz can change based on whether insurance covers it.	Cannot Determine	Not found in the provided label excerpts.	Informational
The price a patient or prescriber sees for Hetlioz can change based on the patient’s benefit structure (copay vs. coinsurance).	Cannot Determine	Not found in the provided label excerpts.	Informational
The price a patient or prescriber sees for Hetlioz can change based on the presence of manufacturer or pharmacy programs.	Cannot Determine	Not found in the provided label excerpts.	Informational
List prices for branded specialty drugs like Hetlioz are often much higher than what insurers and pharmacy benefit managers pay.	Cannot Determine	Not found in the provided label excerpts (no wholesale acquisition cost / PBM discount statements).	Informational
Out-of-pocket cost for Hetlioz usually depends on insurance coverage tier (specialty drug placement and formulary status).	Cannot Determine	Not found in the provided label excerpts.	Informational
Out-of-pocket cost for Hetlioz usually depends on the plan’s deductible status.	Cannot Determine	Not found in the provided label excerpts.	Informational
Out-of-pocket cost for Hetlioz usually depends on whether the patient pays a fixed copay or a percentage (coinsurance).	Cannot Determine	Not found in the provided label excerpts.	Informational
Out-of-pocket cost for Hetlioz usually depends on whether a prior authorization or step-therapy requirement applies.	Cannot Determine	Not found in the provided label excerpts.	Informational
Out-of-pocket cost for Hetlioz may depend on manufacturer assistance availability (if any) and eligibility.	Cannot Determine	Not found in the provided label excerpts.	Informational
Whether alternatives can be cheaper than Hetlioz depends on the specific condition being treated and what the insurer covers.	Cannot Determine	Not found in the provided label excerpts.	Informational

Important Omissions

No label-relevant safety/clinical prescribing information was evaluated because the provided claims were limited to pricing and out-of-pocket determinants.
No information was provided about whether any of these statements are derived from authoritative sources outside the FDA label (e.g., PBM reimbursement studies, CMS datasets, or manufacturer pricing programs).
The FDA label excerpts you supplied do not include pricing/reimbursement content, so label alignment is not assessable from the provided materials.

Unsupported / Hallucinated Content

None identified as contradicted by the provided prescribing information. (However, none of the pricing claims are supported by the provided label excerpts.)

Potential Patient Safety Concerns

List only clinically meaningful concerns.

No clinically meaningful patient safety concerns were identified based on the provided pricing/out-of-pocket statements.

Overall Assessment

The AI statements do not address labeled clinical prescribing content for HETLIOZ (tasimelteon) and instead discuss pricing/out-of-pocket determinants. Because the provided FDA prescribing-information excerpts do not contain any reimbursement or pricing language, the alignment of these claims to authoritative labeling cannot be assessed from the available evidence.

To enable label-based alignment, the exact claim text would need to be cross-referenced against specific label sections that discuss costs/reimbursement (if any), which were not present in the supplied excerpts.